Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

PURPOSE: Primary analysis of VISION showed tepotinib had durable clinical activity in patients with MET exon 14 (METex14) skipping non–small cell lung cancer (NSCLC). We present updated outcomes for clinically relevant subgroups. PATIENTS AND METHODS: This phase II, open-label, multi-cohort study of...

Descripción completa

Detalles Bibliográficos
Autores principales: Le, Xiuning, Sakai, Hiroshi, Felip, Enriqueta, Veillon, Remi, Garassino, Marina Chiara, Raskin, Jo, Cortot, Alexis B., Viteri, Santiago, Mazieres, Julien, Smit, Egbert F., Thomas, Michael, Iams, Wade T., Cho, Byoung Chul, Kim, Hye Ryun, Yang, James Chih-Hsin, Chen, Yuh-Min, Patel, Jyoti D., Bestvina, Christine M., Park, Keunchil, Griesinger, Frank, Johnson, Melissa, Gottfried, Maya, Britschgi, Christian, Heymach, John, Sikoglu, Elif, Berghoff, Karin, Schumacher, Karl-Maria, Bruns, Rolf, Otto, Gordon, Paik, Paul K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2022
Materias:
Clinical Trials: Targeted Therapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365370/
https://www.ncbi.nlm.nih.gov/pubmed/34789481
http://dx.doi.org/10.1158/1078-0432.CCR-21-2733

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365370/
https://www.ncbi.nlm.nih.gov/pubmed/34789481
http://dx.doi.org/10.1158/1078-0432.CCR-21-2733

Ejemplares similares